Clinical Trials Directory

Trials / Completed

CompletedNCT03953976

INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy

INRT- AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy Using Artificial Intelligence-Based Radiomics for Head and Neck Squamous Cell Carcinoma

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
67 (actual)
Sponsor
University of Texas Southwestern Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Elective nodal irradiation has been a longstanding standard-of-care in the management of mucosal squamous cell carcinoma of the head and neck. Recent studies have suggested that reduced elective dose and volume may be a viable approach to improve toxicity. In this study, we are eliminating the elective neck treatment, focusing therapy on involved and suspicious nodes.

Detailed description

We recently completed and reported a successful study (INFIELD) using reduced elective dose (40 Gy) and volume (involved echelons + 1) for oropharynx and larynx cancer. In INRT-AIR (Involved Nodal Radiotherapy using AI-based Radiomics), we are eliminating the elective neck treatment altogether, using radiologic and radiomic-based criteria to focus treatment on the nodes themselves. Eligible patients include previously untreated patients with stage I-IVB oropharynx, larynx and hypopharynx cancer, excluding T1-2 glottic carcinoma. Patients requiring chemotherapy may receive cisplatin, cetuximab, or carboplatin-paclitexel.

Conditions

Interventions

TypeNameDescription
RADIATIONIntensity modulated radiation therapy (IMRT)Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel). 6.5-7 weeks of radiotherapy or chemoradiotherapy

Timeline

Start date
2019-07-23
Primary completion
2022-11-15
Completion
2024-01-22
First posted
2019-05-17
Last updated
2026-02-19
Results posted
2026-02-19

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03953976. Inclusion in this directory is not an endorsement.